Commit ·
efa9849
1
Parent(s): ea2e252
Update README.md
Browse files
README.md
CHANGED
|
@@ -24,7 +24,7 @@ The model should be used with the BioBERT tokeniser. A sample code for getting m
|
|
| 24 |
import numpy as np
|
| 25 |
from transformers import AutoTokenizer
|
| 26 |
from transformers import AutoModelForTokenClassification
|
| 27 |
-
|
| 28 |
tokenizer = AutoTokenizer.from_pretrained('dmis-lab/biobert-v1.1')
|
| 29 |
model = AutoModelForTokenClassification.from_pretrained(r'aakorolyova/reported_outcome_extraction')
|
| 30 |
text = """Compared with placebo plus chemotherapy, pembrolizumab plus chemotherapy improved overall survival in patients with previously untreated, advanced oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more, and overall survival and progression-free survival in patients with oesophageal squamous cell carcinoma, PD-L1 CPS of 10 or more, and in all randomised patients regardless of histology, and had a manageable safety profile in the total as-treated population."""
|
|
|
|
| 24 |
import numpy as np
|
| 25 |
from transformers import AutoTokenizer
|
| 26 |
from transformers import AutoModelForTokenClassification
|
| 27 |
+
|
| 28 |
tokenizer = AutoTokenizer.from_pretrained('dmis-lab/biobert-v1.1')
|
| 29 |
model = AutoModelForTokenClassification.from_pretrained(r'aakorolyova/reported_outcome_extraction')
|
| 30 |
text = """Compared with placebo plus chemotherapy, pembrolizumab plus chemotherapy improved overall survival in patients with previously untreated, advanced oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more, and overall survival and progression-free survival in patients with oesophageal squamous cell carcinoma, PD-L1 CPS of 10 or more, and in all randomised patients regardless of histology, and had a manageable safety profile in the total as-treated population."""
|